Saba Capital Management’s Psyence Biomedical Warrant PBMWW Stock Holding History

Saba Capital Management’s Portfolio PBMWW Stock Details PBMWW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.24K	Hold	297,847	–	–	﹤0.01%	377
2026 Q1	$5.41K	Hold	297,847	–	–	﹤0.01%	368
2025 Q4	$4.71K	Hold	297,847	–	–	﹤0.01%	326
2025 Q3	$7.51K	Hold	297,847	–	–	﹤0.01%	298
2025 Q2	$6.03K	Hold	297,847	–	–	﹤0.01%	295
2025 Q1	$5.05K	Hold	297,847	–	–	﹤0.01%	242
2024 Q4	$4.14K	Hold	297,847	–	–	﹤0.01%	264
2024 Q3	$3.75K	Hold	297,847	–	–	﹤0.01%	323
2024 Q2	$4.41K	Hold	297,847	–	–	﹤0.01%	351
2024 Q1	$21.3K	Buy	+297,847	New	+$18.6K	﹤0.01%	303

Other funds holding PBMWW

HCI

Harraden Circle Investments New York $784M AUM 20.59% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return

MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Calamos Advisors Naperville, Illinois $30.1B AUM 30.03% 1-Year Est. Return

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

TCM

Tenor Capital Management New York $7.09B AUM 3.55% 1-Year Est. Return

Saba Capital Management's PBMWW Position: Q2 2026 in Review

Saba Capital Management held its Psyence Biomedical Warrant (PBMWW) position steady in Q2 2026 at 297,847 shares worth $7.24K. The position accounts for ﹤0.01% of the portfolio, ranked #377.

Saba Capital Management first reported a position in PBMWW in Q1 2024 and has held it in 10 quarters since. The position peaked at $21.3K in Q1 2024. 18 funds tracked by Wall St. Rank hold PBMWW as of Q2 2026.

Saba Capital Management held 297,847 shares of Psyence Biomedical Warrant worth $7.24K as of Q2 2026.
Saba Capital Management left its Psyence Biomedical Warrant share count unchanged in Q2 2026.
Psyence Biomedical Warrant made up ﹤0.01% of Saba Capital Management's portfolio in Q2 2026, its #377 holding.
Saba Capital Management first reported a position in Psyence Biomedical Warrant in Q1 2024 and has held it in 10 quarters since.
Saba Capital Management's Psyence Biomedical Warrant position peaked at $21.3K in Q1 2024.
18 funds tracked by Wall St. Rank held Psyence Biomedical Warrant as of Q2 2026.

Based on Saba Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.